Prosecution Insights
Last updated: April 19, 2026

Examiner: CHATRATHI, ARJUNA P

Tech Center 3700 • Art Units: 3781

This examiner grants 64% of resolved cases

Performance Statistics

63.5%
Allow Rate
-6.5% vs TC avg
255
Total Applications
+23.4%
Interview Lift
1085
Avg Prosecution Days
Based on 200 resolved cases, 2023–2026

Rejection Statute Breakdown

0.6%
§101 Eligibility
14.0%
§102 Novelty
59.0%
§103 Obviousness
16.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18415761 ABSORBENT STRUCTURE FOR ABSORBENT ARTICLES Non-Final OA The Procter & Gamble Company
18492827 ARRAY OF WEARABLE ARTICLES Final Rejection The Procter & Gamble Company
18213401 ABSORBENT ARTICLES CONTAINING WETNESS INDICATING COMPOSITIONS AND METHODS FOR MANUFACTURE Final Rejection The Procter & Gamble Company
17188143 EXTRACORPOREAL CIRCULATION MANAGEMENT DEVICE, EXTRACORPOREAL CIRCULATION DEVICE, AND EXTRACORPOREAL CIRCULATION MANAGEMENT PROGRAM Final Rejection TERUMO KABUSHIKI KAISHA
17325721 ABDOMINAL DRESSING WITH MECHANISM AND MEANS FOR FASCIAL CLOSURE Non-Final OA Solventum Intellectual Properties Company
17773773 FLUSHABLE CATHETER EXTENSIONS AND METHODS OF USING AND MAKING THE SAME Final Rejection Hollister Incorporated
18622604 Air Venting Meter Lid Adapter Final Rejection C. R. Bard, Inc.
18693931 Drain Electrode Non-Final OA UNM Rainforest Innovations
18386550 SURGICAL VACUUM DEVICE Final Rejection LSI Solutions, Inc.
17792686 INTERATRIAL SHUNTS WITH ANCHORING MECHANISMS AND ASSOCIATED SYSTEMS AND METHODS Non-Final OA Shifamed Holdings, LLC
18635810 PACKAGED, SEALED CONTAINER SYSTEM FOR STABLE STORAGE OF AN OXYGEN SENSITIVE PHARMACEUTICAL FORMULATION Non-Final OA Baxter Healthcare SA
18230134 OPTIMIZED CONCAVE MIRROR FOR HORIZONTAL EYE SPRAY APPARATUS WITH ON-AXIS LIGHT GUIDED USER ALIGNMENT Final Rejection Verily Life Sciences LLC
17425361 COMMON CONTACT SURFACES FOR USE IN THE MANUFACTURE, PACKAGING, DELIVERY, AND ASSESSMENT OF BIOPHARMACEUTICAL PRODUCTS Non-Final OA Sio2 Medical Products, LLC
18563672 FLUID COLLECTION SYSTEMS INCLUDING AT LEAST ONE POROUS CARTRIDGE Non-Final OA PUREWICK CORPORATION
17595747 FLUID COLLECTION DEVICES AND SYSTEMS HAVING A FLUID IMPERMEABLE BARRIER WITH A SELECTIVELY MINIMAL HARDNESS, THICKNESS, AND/OR MODULUS OF ELASTICITY Final Rejection PureWick Corporation
18117073 Blood Component Collection Set With Integrated Safety Features Non-Final OA Terumo BCT, Inc.
18624539 PRIMING SYSTEM FOR USE WITH A MEDICAL FLUID SYSTEM Non-Final OA CardiacAssist, Inc.
17706304 OXYGENATOR WITH WOUND FILTER MEMBRANE AND FLOW DIFFUSER Non-Final OA CardiacAssist, Inc.
18590122 UNDERWEAR-TYPE ABSORBENT ARTICLE Non-Final OA Unicharm Corporation
18681675 DILATABLE BILIARY DRAINS Non-Final OA Northwestern Memorial HealthCare
18220122 Connector for Introducing Ambient Air Into a Negative Pressure Wound Therapy System Final Rejection DeRoyal Industries, Inc.
18506414 Device for Establishing the Venous Inflow to a Blood Reservoir of an Extracorporeal Blood Circulation System Final Rejection LivaNova Deutschland GmbH
18552708 ATOMIC LAYER DEPOSITION COATED PHARMACEUTICAL PACKAGING AND IMPROVED SYRINGES AND VIALS, E.G. FOR LYOPHILIZED/COLD-CHAIN DRUGS/VACCINES Non-Final OA SIO2 MEDICAL PRODUCTS, INC.
18012588 ATOMIC LAYER DEPOSITION COATED PHARMACEUTICAL PACKAGING AND IMPROVED SYRINGES AND VIALS, E.G. FOR LYOPHILIZED/COLD-CHAIN DRUGS/VACCINES Final Rejection SiO2 Medical Products, Inc.
18468868 EYEDROP ADMINISTRATIVE DEVICE Non-Final OA PREEMIER, LLC
18177047 APPARATUS AND METHODS FOR POINT-OF-CARE RED BLOOD CELL WASHING Non-Final OA Hanuman Pelican, Inc.
17768997 SAFETY ASSEMBLY FOR THE RECONSTITUTION, THE TAKING AND THE INFUSION OF PHARMACOLOGICAL LIQUIDS Final Rejection NACATUR INTERNATIONAL IMPORT EXPORT S.R.L.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month